• Combining the oncolytic peptide LTX-315 with doxorubicin demonstrates therapeutic potential in a triple-negative breast cancer model 

      Camilio, Ketil Andre; Wang, Meng-Yu; Mauseth, Brynjar; Waagene, Stein; Kvalheim, Gunnar; Rekdal, Øystein; Sveinbjørnsson, Baldur; Mælandsmo, Gunhild M. (Journal article; Tidsskriftartikkel; Peer reviewed, 2019-01-22)
      <i>Background</i> - Immunochemotherapy, the combined use of immunotherapy and chemotherapy, has demonstrated great promise in several cancers. LTX-315 is an oncolytic peptide with potent immunomodulatory properties designed for the local treatment of solid tumors. By inducing rapid immunogenic cell death through the release of danger-associated molecular pattern molecules (DAMPs), LTX-315 is capable ...
    • Oncolytic peptide LTX-315 induces an immune-mediated abscopal effect in a rat sarcoma model 

      Nestvold, Janne M.; Wang, Mengyu; Camilio, Ketil Andre; Zinöcker, Severin; Tjelle, Torunn Elisabeth; Lindberg, Alf; Haug, Bengt Erik; Kvalheim, Gunnar; Sveinbjørnsson, Baldur; Rekdal, Øystein (Journal article; Tidsskriftartikkel; Peer reviewed, 2017-08-17)
      LTX 315 is an oncolytic peptide with potent immunological properties. In the present study, we demonstrate that intratumoral treatment with LTX-315 resulted in a complete regression and systemic immune response in a rat fibrosarcoma model. The treatment was T-cell dependent, and also resulted in an abscopal effect as demonstrated by the regression of distal non-treated lesions. Significant infiltration ...
    • Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival 

      Mathiesen, Randi Margit Ruud; Borgen, Elin; Renolen, Anne; Løkkevik, Erik; Nesland, Jahn M; Anker, Gun Birgitta; Østenstad, Bjørn; Lundgren, Steinar; Risberg, Terje; Mjaaland, Ingvil; Kvalheim, Gunnar; Lønning, Per Eystein; Naume, Bjørn (Journal article; Tidsskriftartikkel; Peer reviewed, 2012-08-14)
      <i>Introduction</i> - Presence of disseminated tumor cells (DTCs) in bone marrow (BM) and circulating tumor cells (CTC) in peripheral blood (PB) predicts reduced survival in early breast cancer. The aim of this study was to determine the presence of and alterations in DTC- and CTC-status in locally advanced breast cancer patients undergoing neoadjuvant chemotherapy (NACT) and to evaluate their ...